Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05239468 · ClinicalTrials.gov registry record · Phase 2
Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC
A Phase 2 study, sponsored by Intercept Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT05239468 is a Phase 2 study that has completed, run by Intercept Pharmaceuticals. The registered enrollment target is 72 participants.
The verdict
NCT05239468, a Phase 2 study, has completed, sponsored by Intercept Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (OCA) in participants with Primary Biliary Cholangitis (PBC).
Interventions
- DRUG Bezafibrate 100 mg
- DRUG Bezafibrate 200 mg
- DRUG Obeticholic Acid 5 mg
- DRUG Obeticholic Acid placebo
- DRUG Bezafibrate Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2022-03-21 |
| Est. Completion | 2025-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05239468
The ClinicalTrials.gov registry entry for NCT05239468 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intercept Pharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bezafibrate 100 mg is the first listed.
NCT05239468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05239468 about?
NCT05239468 is a clinical study titled "Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC". Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (OCA) in participants with Primary Biliary Cholangitis (PBC).
What is the current status of trial NCT05239468?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2022-03-21. Estimated completion is 2025-09-01.
What interventions are being tested in trial NCT05239468?
The interventions under investigation include: Bezafibrate 100 mg (DRUG), Bezafibrate 200 mg (DRUG), Obeticholic Acid 5 mg (DRUG), Obeticholic Acid placebo (DRUG), Bezafibrate Placebo (DRUG).
Who is sponsoring clinical trial NCT05239468?
This trial is sponsored by Intercept Pharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.